全文获取类型
收费全文 | 634篇 |
免费 | 25篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 8篇 |
妇产科学 | 18篇 |
基础医学 | 84篇 |
口腔科学 | 8篇 |
临床医学 | 34篇 |
内科学 | 84篇 |
皮肤病学 | 17篇 |
神经病学 | 13篇 |
特种医学 | 54篇 |
外国民族医学 | 1篇 |
外科学 | 100篇 |
综合类 | 18篇 |
预防医学 | 15篇 |
眼科学 | 17篇 |
药学 | 38篇 |
中国医学 | 13篇 |
肿瘤学 | 146篇 |
出版年
2024年 | 2篇 |
2023年 | 6篇 |
2022年 | 33篇 |
2021年 | 27篇 |
2020年 | 17篇 |
2019年 | 78篇 |
2018年 | 132篇 |
2017年 | 59篇 |
2016年 | 22篇 |
2015年 | 19篇 |
2014年 | 97篇 |
2013年 | 37篇 |
2012年 | 25篇 |
2011年 | 41篇 |
2010年 | 10篇 |
2009年 | 9篇 |
2008年 | 11篇 |
2007年 | 7篇 |
2006年 | 6篇 |
2005年 | 6篇 |
2004年 | 2篇 |
2003年 | 1篇 |
2002年 | 1篇 |
2001年 | 6篇 |
2000年 | 2篇 |
1999年 | 1篇 |
1997年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1982年 | 1篇 |
1981年 | 3篇 |
1978年 | 1篇 |
排序方式: 共有669条查询结果,搜索用时 140 毫秒
91.
Cloning and pharmacological characterization of the guinea pig P2X7 receptor orthologue 总被引:1,自引:0,他引:1
Fonfria E Clay WC Levy DS Goodwin JA Roman S Smith GD Condreay JP Michel AD 《British journal of pharmacology》2008,153(3):544-556
BACKGROUND AND PURPOSE: The human, rat, and mouse P2X(7) receptors have been previously characterized, and in this study we report the cloning and pharmacological properties of the guinea pig orthologue. EXPERIMENTAL APPROACH: A cDNA encoding for the guinea pig P2X(7) receptor was isolated from a guinea pig brain library. The receptor was expressed in U-2 OS cells using the BacMam viral expression system. A monoclonal antibody was used to confirm high levels of cell surface expression and the functional properties were determined in ethidium bromide accumulation studies. KEY RESULTS: The predicted guinea pig protein is one amino acid shorter than the human and rat orthologues and over 70% identical to the rat and human receptors. In contrast to human and rat P2X(7) receptors, 2'-&3'-O-(4benzoylbenzoyl)ATP (BzATP) was a partial agonist of the guinea pig P2X(7) receptor when compared to ATP and acted as an antagonist in some assays. However, as at other species orthologues, BzATP was more potent than ATP. The guinea pig P2X(7) receptor possessed higher affinity for 1-[N,O-bis(5-isoquinoline sulphonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine (KN62), suramin and Coomassie Brilliant Blue than human or rat P2X(7) receptors suggesting that it is pharmacologically different to other rodent or human P2X(7) receptors. CONCLUSIONS AND IMPLICATIONS: The guinea pig recombinant P2X(7) receptor displays a number of unique properties that differentiate it from the human, rat and mouse orthologues and this structural and functional information should aid in our understanding of the interaction of agonists and antagonist with the P2X(7) receptor. 相似文献
92.
93.
Wan Yee Lau Kang Wang Xiu-Ping Zhang Le-Qun Li Tian-Fu Wen Min-Shan Chen Wei-Dong Jia Li Xu Jie Shi Wei-Xing Guo Ju-Xian Sun Zhen-Hua Chen Lei Guo Xu-Biao Wei Chong-De Lu Jie Xue Li-Ping Zhou Ya-Xing Zheng Meng Wang Meng-Chao Wu Shu-Qun Cheng 《肝胆外科与营养》2021,10(6):782
BackgroundA new staging system for patients with hepatocellular carcinoma (HCC) associated with portal vein tumor thrombus (PVTT) was developed by incorporating the good points of the BCLC classification of HCC, and by improving on the currently existing classifications of HCC associated with PVTT.MethodsUnivariate and multivariate analysis with Wald χ2 test were used to determinate the clinical prognostic factors for overall survival (OS) in patients with HCC and PVTT in the training cohort. Then the conditional inference trees analysis was applied to establish a new staging system.ResultsA training cohort of 2,179 patients from the Eastern Hepatobiliary Surgery Hospital and a validation cohort of 1,550 patients from four major liver centers in China were enrolled into establishing and validating a new staging system. The system was established by incorporating liver function, general health status, tumor resectability, extrahepatic metastasis and extent of PVTT. This staging system had a good discriminatory ability to separate patients into different stages and substages. The median OS for the two cohorts were 57.1 (37.2–76.9), 12.1 (11.0–13.2), 5.7 (5.1–6.2), 4.0 (3.3–4.6) and 2.5 (1.7–3.3) months for the stages 0 to IV, respectively (P<0.001) in the training cohort. The corresponding figures for the validation cohort were 6.4 (4.9–7.9), 2.8 (1.3–4.4), 10.8 (9.3–12.4), and 1.5 (1.3–1.7) months for the stages II to IV, respectively (P<0.001). The mean survival for stage 0 to 1 were 37.6 (35.9–39.2) and 30.4 (27.4–33.4), respectively (P<0.001).ConclusionsA new staging system was established which provided a good discriminatory ability to separate patients into different stages and substages after treatment. It can be used to supplement the other HCC staging systems. 相似文献
94.
miR-363-3p has been shown to suppress tumor growth and metastasis in various human cancers. However, the
function of miR-363-3p in osteosarcoma (OS) has not been determined. In our study, we found that the expression of miR-363-3p was significantly downregulated in OS tissues compared with adjacent normal tissues.
miR-363-3p expression was associated with the poor overall survival rate of OS patients. Moreover, we found
that overexpression of miR-363-3p markedly inhibited the proliferation, migration, and invasion of U2OS and
MG63 cells. Moreover, we found that SOX4 was a direct target of miR-363-3p in OS cells. Overexpression
of miR-363-3p significantly inhibited the expression of SOX4. Expression levels of miR-363-3p and SOX4
were negatively correlated in OS tissues. Finally, we found that restoration of SOX4 attenuated the suppressive
effects of miR-363-3p on the proliferation, migration, and invasion of U2OS and MG63 cells. Therefore, our
findings demonstrated that miR-363-3p served as a tumor suppressor in OS tissues by targeting SOX4. 相似文献
95.
96.
Masatoshi Kondo Yoshikazu Uchiyama 《Journal of neuroradiology. Journal de neuroradiologie》2018,45(4):236-241
Background
To investigate the potential to predict prognosis of glioblastoma (GBM) patients by analysis of the broader and lower values in the lower distribution of apparent diffusion coefficient (ADCL) (B&L-ADCL) values in the ADC histogram.Background
Presurgical publicly available diffusion-weighted images (DWI) and contrast-enhanced T1-weighted images from 76 GBM patients were analyzed. With applied 2-mixture normal distribution in the ADC histogram of enhanced lesions on T1-weighted images, the mean and width of ADCL were analyzed. We dichotomized the lower mean of ADCL (L-ADCL) and the broader width of ADCL (B-ADCL) at their own average. B&L-ADCL was defined as B-ADCL with L-ADCL. Progression-free survival (PFS) and overall survival (OS) were determined by using Cox proportional hazards analysis and the Kaplan–Meier method with the log-rank test. The difference between PFS and OS was calculated.Results
Six (7.89%) patients had B&L-ADCL values. B&L-ADCL was strongly associated with poor PFS (hazard risk: 5.747; P = 0.002) and OS (hazard risk: 3.331; P = 0.018). There were significant differences in PFS (median, 77 vs. 302 days; P < 0.001) and OS (median, 199 vs. 472 days; P = 0.004) between the patents with and without B&L-ADCL. There was no significant difference in the OS–PFS duration difference between the patients with (median, 79 days) and without B&L-ADCL (median, 132 days) (P = 0.348).Conclusion
In this study, B&L-ADCL from pretreatment ADC analysis predicted poor PFS. B&L-ADCL may indicate higher cellularity and heterogeneity in GBM tumor tissue. 相似文献97.
98.
Freja Lærke Sand Ditte Maria Bjerno Nielsen Marie Hoffmann Frederiksen Christina Louise Rasmussen Susanne K. Kjaer 《Gynecologic oncology》2019,152(1):208-217
The tumor suppressor proteins p16 and p53 have been suggested to have prognostic value in some human papillomavirus (HPV)-associated cancers, however, this has been less well established for vulvar cancer. The aim of this review and meta-analysis was to examine the prognostic value of p16 and p53 expression status on survival after vulvar squamous cell carcinoma (VSCC). We conducted a thorough systematic literature search of multiple databases to identify studies examining survival after histolocally verified VSCC that were tested for p16 and/or p53. A total of 18 eligible studies were included. Using a fixed-effects model we calculated study-specific and pooled hazard ratios (HRs) of 5-year overall survival (OS). In the analyses of OS, we included 475 VSCC cases tested for p16 expression of which 38% were p16 positive. The pooled HRp16 was 0.40 (95% CI: 0.29–0.55). In addition, the majority of results from studies with adjusted analyses on the prognostic value of p16 indicated that p16 expression status could be an independent prognostic marker for OS in women diagnosed with VSCC, and the same pattern was seen for disease specific survival (DSS). We also included 310 VSCC cases tested for p53 expression of which 54% were p53 positive. The pooled HRp53 was 1.81 (95% CI: 1.22–2.68) indicating that p53 positive VSCC have a significantly lower 5-year OS compared to p53 negative. The results in relation to p53 reported from adjusted analyses OS and on DSS and disease free survival were more equivocal. This meta-analysis and review suggests that p53 and especially p16 expression status are of prognostic importance in women diagnosed with VSCC. This may be clinically important in the future design of targeted therapy and when planning the optimal follow-up strategy. Future studies should include the combined use of biomarkers such as p16, p53 and HPV status. 相似文献
99.
Meredith McKean Junna Oba Junsheng Ma Katherine G Roth Wei-Lien Wang Mariana P. Macedo Fernando C.L. Carapeto Lauren E. Haydu Alan E. Siroy Phuong Vo David S. Hong Agda K. Eterovic Keyur Pravinchandra Patel Roland L Bassett Elizabeth A. Grimm Alexander J. Lazar Scott E. Woodman 《The Journal of investigative dermatology》2019,139(3):728-731
100.
Siddharth A. Padia Guy E. Johnson Kathryn J. Horton Christopher R. Ingraham Matthew J. Kogut Sharon Kwan Sandeep Vaidya Wayne L. Monsky James O. Park Renuka Bhattacharya Daniel S. Hippe William P. Harris 《Journal of vascular and interventional radiology : JVIR》2017,28(6):777-785.e1